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Inflammatory cytokines and endogenous anti-oxidants are variables affecting disease progression in
multiple sclerosis (MS). Here we demonstrate the dual capacity of triterpenoids to simultaneously repress
production of IL-17 and other pro-inflammatory mediators while exerting neuroprotective effects directly
through Nrf2-dependent induction of anti-oxidant genes. Derivatives of the natural triterpene oleanolic
acid, namely CDDO-trifluoroethyl-amide (CDDO-TFEA), completely suppressed disease in a murine
model of MS, experimental autoimmune encephalomyelitis (EAE), by inhibiting Th1 and Th17 mRNA and
cytokine production. Encephalitogenic T cells recovered from treated mice were hypo-responsive to myelin
antigen and failed to adoptively transfer the disease. Microarray analyses showed significant suppression of
pro-inflammatory transcripts with concomitant induction of anti-inflammatory genes including Ptgds and
Hsd11b1. Finally, triterpenoids induced oligodendrocyte maturation in vitro and enhanced myelin repair in
an LPC-induced non-inflammatory model of demyelination in vivo. These results demonstrate the unique
potential of triterpenoid derivatives for the treatment of neuroinflammatory disorders such as MS.

T

he dynamic regulation of cytoprotective genes in response to inflammatory mediators contributes to the
relapsing-remitting nature of multiple sclerosis (MS)1. In murine models of MS, initiation of disease requires
induction of a Th17 T cell response with disease manifestations ultimately resulting from activated macrophages which phagocytose myelin and contribute to degeneration of myelin sheaths, oligodendrocytes and
axons2. Activated monocytes and macrophages produce inflammatory mediators, including nitric oxide and
reactive oxygen species (ROS), which contribute to the development and progression of the disease3,4. Generation
of ROS in brain parenchyma contributes to lesion persistence by mediating oligodendroglial damage and axonal
injury5,6, and reduced serum levels of antioxidants have been observed in patients with MS7.
The central nervous system is endowed with several protective mechanisms consisting of enzymatic and nonenzymatic antioxidants whose expression is regulated through the transcription factor nuclear factor-E2-related
factor (Nrf2) and the antioxidant response element (ARE). In humans with MS, enhanced expression of Nrf2/AREregulated antioxidants in the brain is indicative of the response to oxidative stress, and in mice disruption of Nrf2
gene expression (Nrf22/2 mice) leads to exacerbation of clinical and pathological symptoms of experimental autoimmune encephalomyelitis (EAE)8. Nrf22/2 mice are also hypersensitive to LPS-induced neuroinflammation9 and
Nrf2 is reported to be involved in maintaining CNS myelin10. To date, over 200 Nrf2/ARE-driven genes involved in
detoxification and antioxidant defense have been identified, out of which superoxide dismutases (SOD), glutathione
peroxidases, GPxs11, catalases4,12,13, and hemeoxygenases-1 (Hmox-1)14,15 are all modulated during MS.
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The families of natural and synthetic triterpenoids have recently
emerged as potent regulators of the Nrf2/ARE pathway. Triterpenoids represent a broad category of molecules ubiquitously present
in the plant kingdom16,17, and used widely in Asian medicine (usually
in the form of herbal extracts)18. Among these natural triterpenoids,
the natural pentacyclic triterpene oleanolic acid (OA) displays numerous biological properties with therapeutic potential18,19. Both OA and
herbal extracts containing OA are known for their immunomodulatory properties20 and have been shown to reduce clinical pathology
associated with neuroinflammation and EAE21,22.
Oleanolic acid has served as the platform for synthesis of several
novel triterpenoids, including 2-cyano-3,12-dioxooleana-1,9(11)-dien
-28-oic acid methyl ester (CDDO-Me) which is currently in Phase III
clinical trials in patients with diabetic nephropathy23,24. In preclinical
studies, CDDO-methyl amide (CDDO-MA) was shown to exert neuroprotective effects through potent activation of the Nrf2/ARE pathway and is neuroprotective in preclinical model systems, including a
transgenic model of Alzheimer’s disease25. Further derivatization of
CDDO to yield an imidazolide (CDDO-Im), an ethyl amide, (CDDOEA), or a trifluoroethyl amide (CDDO-TFEA), resulted in significantly
increased biological activity26, and enhanced capacity to cross the
blood brain barrier (BBB)27.
In this study we reveal the mechanisms mediating neuroprotective
effects of three CDDO derivatives CDDO-Me, CDDO-EA and
CDDO-TFEA in the treatment of EAE. Daily systemic administration of these compounds alone significantly alleviates the clinical
symptoms of disease. We show that CDDO-TFEA not only induces
Nrf2 expression and signaling both in affected CNS tissue as well as
in peripheral lymphocytes, but also leads to global suppression of
inflammatory response genes in mice with EAE and suppression
of disease associated cytokines, particularly interleukin-17 (IL-17).
Lastly, CDDO-TFEA protects against non-inflammatory lysophosphatidyl choline (LPC)-induced demyelination suggesting a direct
action of this molecule on myelin preservation and repair. These
results reveal the potency and unique mechanisms through which

novel synthetic triterpenoids, specifically CDDO derivatives, suppress disease progression in the setting of inflammatory neurodegenerative disease.

Results
CDDO derivatives promote complete resolution of EAE. To
investigate the efficacy of selected synthetic triterpenoids (Fig. 1A),
mice were immunized with either MOG 35–55 (C57BL/6 mice) or
PLP (139–151) (Balb/C mice) and received systemic administration
of either CDDO-Me, CDDO-EA, or CDDO-TFEA after the onset of
disease. Administration of triterpenoids every alternate day for 10
days significantly improved survival (Fig 1B) and led to complete
abrogation of clinical symptoms within the first two weeks of
treatment, regardless of disease score at the onset of treatment
(Fig. 1 C). Recrudescence of disease symptoms was significantly
delayed after treatment with CDDO-TFEA, when compared to
CDDO-Me (Fig. S1-A) and CDDO-EA (Fig. S1-B). Re-exposure of
these mice to the same molecule resulted in complete suppression of
clinical symptoms in all treatment groups. The severity of symptoms
at disease relapse was low and survival was greater than 90% for mice
treated with either the ethyl-amide or trifluoroethylamide derivatives. The beneficial effects of CDDO-TFEA were reproducible in
the remitting relapsing model of PLP (139–151)-induced EAE
(Fig. 1D). The effect of these small molecules on EAE disease
progression may involve a combination of suppressive activity on
the peripheral immune system and direct neuroprotective effects
in the CNS. The former is supported by our observation that
lymphocytes collected from mice immunized with MOG (35–55)
and subsequently exposed to CDDO-TFEA completely failed to
adoptively transfer disease to untreated mice (Fig. S2).
CDDO-TFEA attenuates CNS inflammation and demyelination
in mice with EAE. To assess the effects of CDDO-TFEA and other
derivatives on EAE-associated CNS pathology, lumbar spinal cord
and brain stem were obtained from mice either at the peak of disease

Figure 1 | Systemic administration of CDDO derivatives ameliorates the severity of EAE. (A) Chemical structure of the parent molecule, CDDO, and its
derivatives used in this study. (B) Survival of mice was recorded (Kaplan-Meier survival curve) within 3 months of MOG (35–55) immunization.
(C) C57Bl/6 mice were pooled at different clinical scores and CDDO-TFEA was administered by i.p. injections (as described in methods section) on
alternate days at the indicated time points; a specific clinical score was assigned to each mouse at 48 hr intervals and these scores are depicted as mean
clinical scores. (D) SJL mice were immunized with PLP (139–151) and treated with CDDO-TFEA on alternate days during the indicated time points. All
data are presented as the mean 6 S.E.M. (n5 10–12 mice in each group).
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severity or at a point when disease scores approached baseline.
Independent histological analysis of brain stem (Fig. S3) and spinal
cord demonstrated reduced inflammation (Fig. 2A–C & 2M) and
minimal demyelination (Fig. 2D–F & 2N), in CDDO-TFEA-treated
animals when compared with the untreated control group. There was
a significant reduction in the number of F4/80 (macrophage and
microglia; Fig. 2G–I) and myeloperoxidase (neutrophil, Fig. 2J–L)
positive cells in the lumbar spinal cord of mice treated with CDDOTFEA. These data support a conclusion that suppression of immune
and inflammatory cell populations is one mechanism underlying the
response to synthetic triterpenoids in EAE.
Treatment with CDDO-TFEA diminishes inflammatory cytokine
levels. Our laboratory and others have shown direct suppressive effects
of triterpenoids on immune cell activation and on receptor-mediated
activation of signaling intermediates including Stat3 and NFkB28,29. To
determine whether triterpenoid suppression of CNS infiltration by
immune cells in mice with EAE was linked to suppression of the
immune response in the periphery, we first analyzed serum and
supernatants of cultured peripheral blood lymphocytes harvested
from mice with EAE and re-stimulated ex vivo in the presence or
absence of CDDO-TFEA (Fig. 3A–G). A significant reduction in
Th1 and Th17 cytokines (i.e. IL6, IL17, IFNc, TNFa and GMCSF)
was observed while IL-2 production was not altered significantly.
Lymphocytes collected from spleen and inguinal lymph nodes of
mice 21 days after MOG (35–55) injection secreted several cytokines
when restimulated with MOG (35–55) peptide ex vivo, but production
of IL2, IL4, IL6, IL17, TNF-a, IFN-c and GMCSF was significantly
lower in lymphocytes harvested from mice treated with CDDO-TFEA.
When these data were normalized for cell proliferation (to account for
effects of CDDO-TFEA on cell growth) the differences in IL17 and
GMCSF production remained highly significant.

CDDO-TFEA suppresses antigen-specific lymphocyte responses
and modulates Hmox-1 and iNOS protein expression. The data
presented thus far suggest that triterpenoids may suppress EAE
through direct effects on immune cell activation and function. We
hypothesized that CDDO-TFEA might impair development of an
antigen-specific memory response to MOG (35–55) through direct
suppression of T cell activation or cytokine driven proliferative
expansion. Here we show that CDDO-TFEA treatment significantly
inhibited the responses to CD3/CD28 and IL7 both alone and
in combination (Fig. S4). Interleukein-7 (IL7) is a non-redundant
cytokine essential for T cell survival and development and T cell
memory30. Patients suffering with MS have a higher level of IL7 and
IL7R-alpha in the cerebrospinal fluid compared with patients suffering
from other non-inflammatory neurological disorders31. CDDO-TFEA
significantly suppressed IL-7 stimulated in vitro proliferation of
both quiescent and activated T cells isolated from spleen and lymph
nodes of mice immunized with MOG (Fig. S4). We assessed the
ex vivo responsiveness of lymphocytes isolated from lymph nodes
and spleen of either a) control mice, b) MOG(35–55)-immunized
mice with symptoms of EAE or c) MOG(35–55)-immunized mice
following treatment with CDDO-TFEA. Lymphocytes derived from
lymph nodes of symptomatic mice restimulated with MOG (35–55) in
vitro had a more than 5-fold greater proliferative response relative to
control lymphocytes, but this response was significantly diminished in
cultures of lymphocytes isolated from mice treated with CDDO-TFEA
in vivo. In either case, the in vitro treatment of these cells with CDDOTFEA completely blocked proliferation in response to MOG (35–55)
(Fig. 4A). These data demonstrate a direct suppression of the
lymphocyte proliferative response to antigen and IL7 stimulation by
CDDO-TFEA and related triterpenoids.
Triterpenoids have also been shown to control inflammation by
suppressing expression of inducible nitric oxide synthase (iNOS) in

Figure 2 | Decreased inflammation and preservation of myelin content after CDDO-TFEA treatment. Mice were sacrificed after MOG (35–55)
immunization either at the peak of clinical symptoms or at a clinical score of zero and after respective treatments with either vehicle control or CDDO-TFEA
and CNS tissues were subjected to histopathological analysis. Representative sections of lumbar spinal cord (A–L) from control mice with clinical signs of
EAE or from mice treated with CDDO-TFEA were stained with hematoxilin and eosin to assess inflammation (A–C), with Luxol fast blue to assess myelin
content (D–F), with F4/80 to stain macrophages and microglia (G–I) and with myloperoxidase (MPO) to stain neutrophils (J–L). Arrows indicate
inflammatory cellular infiltrates (B), demyelinated areas (E) and macrophage and neutrophil infiltrates (H & K). A pathologist blinded to subject identity
scored sections taken from each animal for (M) inflammation and (N) demyelination on the scale of 0 to 3 (Scale bars, 100mm). **, P , 0.01, Student’s t test.
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Figure 3 | CDDO-TFEA treatment suppressed production of key inflammatory cytokines by lymphocytes during EAE. Serum was collected from mice,
including controls, mice with EAE (at clinical score 5) and mice with EAE following treatment with CDDO-derivatives both at the peak of disease severity
and after they reached a clinical score 0. Production of cytokines from peripheral lymphocytes obtained from these mice was determined after culturing
them for 72 hrs ex vivo. ELISA was performed to detect cytokine levels of IL-2 (A), IL-4 (B), IL-6 (C), IL-17 (D), IFNc (E), TNF-a (F) and GMCSF (G). All
data are presented as the mean 6 SEM (n 5 6). **, P , 0.01, *, P , 0.05, Student’s t test.

Figure 4 | CDDO-TFEA inhibits lymphocyte proliferation and modulates iNOS and Hmox-1 protein expression in the CNS of affected mice.
(A) Lymphocytes were collected from control mice, mice with EAE (at clinical score 5) or from mice with EAE following treatment with CDDO-TFEA (at
clinical score 0) and cultured for 72 hrs in the presence or absence of MOG (35–55), with or without CDDO-TFEA. During last 16 hrs, 3H-thymidine was
added to cultures and the incorporated amount of 3H-thymidine in cells was measured as CPM. Protein lysates were prepared from lumbar spinal cord
(B) and brain stem (C) of control mice, mice with EAE (at clinical score 5) or mice with EAE following CDDO-TFEA treatment (at clinical score 0) and
subjected to Western blot analysis to check iNOS and Hmox-1 protein levels. Equal loading of samples was confirmed by actin immunodetection. Data is
presented as the mean 6 SEM (n 5 6). ***, P , 0.001, **, P , 0.01, Student’s t test.
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macrophages. CNS levels of iNOS increase over the course of
EAE32–35, resulting in prolonged exposure to nitric oxide36 which is
cytotoxic37 and promotes inflammation38. We found elevated levels
of iNOS present in the lumbar spinal cord (Fig. 4B) and brain stem
(Fig. 4C) of mice with EAE that were reduced significantly after
CDDO-TFEA treatment. When the same tissues were evaluated
for the expression of Hmox-1, we observed a reciprocal relationship.
Prior reports have shown a link between hemin-induced Hmox-1
expression and reduced clinical severity of EAE in rats, whereas tin
mesoporphyrin, a well-known inhibitor of Hmox-1 markedly exacerbated EAE15. Moreover, induction of EAE in Hmox1-/- mice led
to enhanced CNS demyelination, paralysis, and mortality39. The significant up-regulation of Hmox-1 protein in brain stem and lumbar
spinal cord after CDDO-TFEA treatment suggests a possible mechanism through which this small molecule may be exerting neuroprotective effects in EAE.
Concomitant regulation of Nrf2-dependent and inflammatory
gene transcription. The observed induction of Hmox-1 protein in
CNS tissues following CDDO-TFEA exposure is consistent with the
ability of the triterpenoids to activate Nrf2-dependent expression of
the Hmox-1 gene. We used real-time PCR to evaluate the expression
of Hmox-1 and several inflammation-related genes (including IFNc, IL-17 and iNOS) in total CNS tissue (Fig. 5A–B) and in splenocytes
(Fig. 5C) and in mononuclear cells isolated from the CNS (Fig. 5D)
of mice with EAE. A significant increase in Nrf2 and Hmox-1 transcripts was detected in lymphocytes of mice treated with CDDOTFEA during the course of disease (Fig. 5A–C), and in mononuclear
cells isolated from the CNS (Fig. 5D). Moreover, CDDO-TFEA
significantly induced Nrf2 and Hmox-1 gene expression by encephalitogenic splenocytes cultured in the presence of MOG (35–55)
(Fig. 5C).
The pathogenic role of IL-17 in EAE has been substantiated by
studies in mice deficient in IL-17 or the IL-17-inducing cytokine IL2340,41. We observed complete suppression of IFN-c and IL-17 gene
expression in total CNS tissue (Fig. 5A–B) as well as in mononuclear cells isolated from brain stem and lumbar spinal cord (Fig. 5D)
after CDDO-TFEA treatment. Moreover, CDDO-TFEA significantly

reduced both IFN-c and IL-17 expression by lymphocytes isolated
from mice immunized with MOG (35–55), when these cells were reexposed to MOG (35–55) in vitro (Fig. 5C). Collectively, these data
highlight the multifunctional nature of the synthetic triterpenoids
and the central role of Nrf2-mediated induction of pathways that
combat oxidative stress, including the Hmox-1 pathway. The data
also suggest the observed triterpenoid effect involves regulation of
immune cells both at the site of disease and in the periphery.
CDDO-TFEA suppresses non-inflammatory LPC-induced
demyelination. The data presented thus far suggests that neuronal
integrity is maintained by CDDO-TFEA during EAE induction.
However, the question remains whether this effect of CDDOTFEA is solely due to immune suppression or whether triterpenoids also exert direct effects on myelin stability or regeneration.
To address this question we utilized the well-established noninflammatory lysophosphatidyl choline (LPC)-induced rodent
model of myelin injury. Direct injection of LPC into neural tissue
produces a localized vesicular demyelination of neurons that spares
axons42. In the LPC-induced demyelination paradigm, a small
amount of exogenous LPC injected into the dorsal columns of the
thoracic spinal cord activates membrane bound phospholipase-A2
which then hydrolyzes the lecithin of myelin leading to membrane
solubilization and demyelination with fully developed lesions at
2 days post-injection43. To test the efficacy of CDDO-TFEA on
LPC-induced de-myelination, a total of 12 rats were subjected to
LPC injection within dorsal column of spinal cord; 6 of these also
received 10 nM CDDO-TFEA with LPC injection and then again at
the site of injury 48 hours after LPC injection. Tissues were removed
7 days following injury and processed for immunostaining with antiMBP antibody (for myelin), anti-GFAP antibody (for astrocytes) and
anti-NG2 antibody (for oligodendrocytes).
Control mice (injected with PBS) exhibit intact myelin and a normal distribution of astrocytes (Fig. 6A–D) and oligodendrocytes (Fig.
S5A–D). However, at the site of LPC injection neurons were completely demyelinated (Fig. 6G & Fig. S4G), astrocytes formed a glial
scar around the demylinated area (Fig. 6F and 6H) and oligodendrocytes were recruited around demylinated axons (Fig. S5F and S5H).

Figure 5 | CDDO-TFEA treatment modulates both antioxidant and inflammatory gene transcription in the CNS and in peripheral lymphocytes. Data
represent the fold increase in gene expression levels as detected by quantitative PCR performed on mRNA collected from either (A–B) total CNS tissue,
(C) peripheral lymphocytes or (D) mononuclear cells collected from the CNS tissues of control mice or from those with EAE (at the peak of the disease)
or from mice with EAE following treatment with CDDO-TFEA (when clinical scores returned to baseline). All data are the mean 6 SEM. **, P , 0.01,
Student’s t test.
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Myelin was significantly protected in the CDDO-TFEA treated group
(Fig. 6K and Fig. S5K), with a comparatively normal distribution of
astrocytes and oligodendrocytes. These data were further confirmed
by toluidene blue staining and electron microscopy (Fig. 6M–R). We
observed completely naked axons at the site of LPC injection (Fig. 6N
& 6Q) while administration of CDDO-TFEA preserved myelin at the
site of LPC injection (Fig. 6O and 6R), as defined by the percentage of
myelinated axons and their G ratios in the dorsal horn of the spinal
cord at the site of LPC injection (Fig. 6S–T).
The data above indicate that CDDO-TFEA promotes preservation
of myelin at the site of injury, but it is also possible that CDDO-TFEA
may additionally promote myelin repair by facilitating oligodendrocyte maturation. To address this question, oligodendrocytes

harvested from the CNS of day E18 rat embryos and were cultured
for 10 days in either the presence or absence of CDDO-TFEA.
CDDO-TFEA significantly enhanced maturation of oligodendrocyte
precursors as shown by expression of maturation markers A2B5
(Fig. 7A–F & 7M) and O4 (Fig. 7G–L & 7N). These data indicate
that during EAE, CDDO-TFEA and related synthetic triterpenoids
act as multifunctional agents, both suppressing the immune response
while also acting directly on neurons to protect them from the
demyelination process and to promote myelin repair.
A unique triterpenoid-modulated transcriptome underlies the
resolution of EAE. To better characterize the triterpenoid modulated transcriptome in EAE we performed a gene microarray

Figure 6 | CDDO-TFEA is neuroprotecive in the LPC-induced model of demyelination. Immunostaining of tissue sections prepared from dorsal
columns of the thoracic spinal cord of rats at the site of injection of either PBS (A–D) or LPC (E–H) or LPC1 CDDO-TFEA (I–L). Immunohistochemistry
was performed with an anti-MBP antibody (for myelin), anti-GFAP antibody (for astrocytes) and anti-NG2 antibody (for oligodendrocytes). All images
are taken at 200X magnification. Tissue sections prepared from spinal cord segments at sites injected either with LPC or LPC followed by CDDO-TFEA
were subjected to toludene blue staining (M–O) or electron microscopy (P–R) to analyze the myelin content on neurons at the site of each lesion. G-ratios
of the axons in dorsal columns (S) and quantification of the percentage of demyelinated and myelinated axons in dorsal columns of spinal cord at the site
of LPC injection (T) are shown here.
SCIENTIFIC REPORTS | 1 : 201 | DOI: 10.1038/srep00201
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Figure 7 | CDDO-TFEA induces early oligodendrocyte maturation. Total brain cells prepared from P3 rat pups were cultured with vehicle (A–C and
G–I) or with 10 nM CDDO-TFEA (D–F and J–L) for 3 days (A, D, G, J), 6 days (B, E, H, K), or 10 days (C, F, I, L). Cells were fixed and immunostained
using antibodies against A2B5 to detect immature oligodendrocyte precursor cells (A–F) or against O4 to detect mature oligodendrocytes (G–L). (Scale
bar is 100 mm). Quantitative analysis of the percentage of (M) A2B5 or (N) O4 positive cells after different days of CDDO-TFEA treatment is shown. Data
are the mean 6 SEM. **, P , 0.01, *, P , 0.05, Student’s t test.

(Ilumina Sentrix array Ref. 8v1.1) on lumbar spinal cord, directly
comparing tissues collected from control mice and from mice
following induction of EAE, with or without exposure to CDDOTFEA. A total of 1433 genes were found to be differentially
modulated in mice at the peak of EAE clinical scores compared to
control mice (Fig. 8A). Among them, 135 genes known to be
involved either in the cellular stress response or in inflammation
were significantly altered by CDDO-TFEA treatment, and in most
instances their expression returned to baseline (Fig. 8B–D). However, the induction of 11b-hydroxysteroid dehydrogenase type 1
(11bHSD1) and of prostaglandin D2 synthase (PGDS) suggests
that activation of steroid and prostaglandin biosynthetic pathways
may contribute to the suppression of CNS inflammation by triterpenoids. We validated these gene array results by performing real
time PCR on 9 different genes (Fig. 8E). The data suggest that
inflammation driven suppression of both 11bHSD1 and of PGDS
is reversed by exposure to CDDO-TFEA.

Discussion
Multiple mechanisms operant in MS culminate ultimately in the
generation of a highly oxidative microenvironment that is responsible for tissue injury and neurodegeneration44,45. The data presented
here add to a growing body of literature that strongly support the
clinical development of the family of natural and synthetic triterpenoids as chemopreventive and therapeutic agents in the context of
neuro-inflammatory and neurodegenerative diseases, and specifically in the context of MS. While neuroprotective effects of administered exogenous antioxidants have been reported in EAE5,46,
pursuit of strategies that employ newer agents such as synthetic
triterpenoids to induce endogenous enzymatic antioxidants should
be a more efficient means to inhibit the detrimental effects of ROS
and thereby serve as an effective form of chemoprevention for MS.
Synthetic oleanane triterpenoids have emerged as a potent class of
pharmacologic agents capable of strongly inducing the Nrf2-ARE
axis, and this mechanism has been identified as playing a principal
SCIENTIFIC REPORTS | 1 : 201 | DOI: 10.1038/srep00201

role in the neuroprotective effects of CDDO derivatives in a variety of
models of neurodegenerative disorders27. For example, in the murine
SOD-1 model of Amyotrophic Lateral Sclerosis (ALS)47, exposure to
CDDO-EA and CDDO-TFEA results in nuclear translocation of
Nrf2 in cells expressing the SOD-1 mutant, and suppressed disease
progression whether treatment was initiated in asymptomatic mice
or at the onset of clinical manifestations. While the clinical response
observed in the EAE model may be attributed to effects on Nrf2
expression and function, triterpenoids are multifunctional agents
and it is quite likely that multiple targets participate in conferring
protection in the setting of a complex neurodegenerative process like
MS. For example, a role for Stat3 not only in the genesis of Th17
cells but also in the development of EAE has been defined48–50. Our
laboratory and others have shown that Stat3 is a direct target of
the synthetic triterpenoids28,51. Our demonstration that triterpenoid
exposure following induction of EAE significantly represses both
IL-17 mRNA and protein expression suggests that this mechanism
may also contribute to the overall clinical response to triterpenoids in
the EAE model.
It is noteworthy that the link between an induction of Hmox-1 and
repression of the development of a Th17 reponse has also been
demonstrated for other activators of Hmox-1 in preclinical models
of EAE and inflammatory bowel disease (IBD). Hemin, a potent
inducer of Hmox-1 and activator of Nrf252, suppresses the development of IBD in mice exposed to dextran sodium sulfate (DSS) and
this effect is also associated with a significant reduction in the production of IL-1753. Similarly, intraperitoneal administration of erythropoietin to MOG-EAE mice significantly reduced severity of
disease in a manner that correlated with potent upregulation of
Hmox-1 in the CNS and spleen and with a reduction of Th-17 T cell
subsets54. Finally, the observation that IL-17 might act to directly
suppress the expression of Hmox-1 in the context of an inflammatory response argues that the balance between these two factors may
in fact be an important determinant of disease expression. Thus
the unique capacity of triterpenoids to simultaneously repress IL-17
7
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Figure 8 | Microarray analysis of CNS tissues reveals global suppression of inflammatory genes by CDDO-TFEA in mice with EAE, with a concomitant
induction of genes linked to resolution of inflammation. Gene microarray analysis using Ilumina Sentrix array Ref. 8v1.1, using mRNA collected from
lumbar spinal cord of control mice and mice with EAE treated either with vehicle control or with CDDO-TFEA. (A) Heat map of 1433 genes differentially
expressed in EAE mice compared to control mice. (B) Heatmap of 135 genes significantly altered by CDDO-TFEA treatment. (C) Magnified heat map
(from panel B) of genes either down-regulated during EAE or (D) up-regulated during EAE, and their return to baseline after CDDO-TFEA treatment.
(E) Quantitative PCR was performed using selected probes (as described in material method section) and RNA collected from affected CNS tissue of mice
induced to develop EAE and treated with either CDDO-TFEA or vehicle control. b-actin levels were tested to normalize the amount of RNA and relative
fold induction of transcript was calculated by comparing the basal level of expression of selected genes in normal mouse tissues. All data are the
mean 6 SEM. **, P , 0.01, Student’s t test.
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expression through inhibition of Stat3 and to activate HO-1 through
Nrf-2 suggests their utility for treatment of MS.
It is intriguing to find the induction of both 11b-hydroxysteroid
dehydrogenase type 1 (11bHSD1) and of prostaglandin D2 synthase
(PGDS) in the CNS in mice exposed to CDDO-TFEA. It has been
suggested that a local deficit of cortisol in the CNS may underlie the
relapsing-remitting nature of MS, perhaps secondary to poor local
activation of cortisone via 11b-hydroxysteroid dehydrogenase type 1
(11bHSD1)55. MS patients have been found to maintain normal cortisol concentrations in serum yet exhibit lowered cortisol levels in the
CSF during acute relapses. Although 11bHSD1 was not found to be
expressed within active plaques, the significant induction in myelinloaded macrophages in vitro suggests that production of this enzyme
by infiltrating macrophages may contribute to the self-limiting
nature of MS lesion development. Similarly, a reduction in the intrathecal synthesis of prostaglandin D2 synthase (PGDS) has
been documented during acute inflammatory demyelination56, and
enhanced biosynthesis of prostaglandin (PG)D2 and subsequent
formation of 15-deoxy-D-PGJ2 has been implicated in the resolution
of inflammation57. It is intriguing that 15-PGJ2 has been shown to
activate Nrf2 signaling and to induce Hmox-1 in a manner similar to
CDDO58 thus demonstrating the capacity to contribute to the endogenous anti-oxidant response and raising the question whether the
observed clinical response to triterpenoids shown here might reflect
their capacity to mimic many of the functions of this endogenous
anti-inflammatory protein.
Lastly, our data in the model of LPC-induced demyelination suggest that the efficacy of triterpenoids in the context of EAE is linked
to a capacity to regulate astrocyte activation and to preserve CNS
myelin. Nrf-2-/- mice develop a spontaneous progressive leukoencephalopathy, with vacuolar degeneration that is linked to myelin
unwinding, intramyelinic cysts and oxidative damage to myelin10.
Similarly, the observation that the anti-oxidant fumaric acid (FA)
can preserve myelin and axonal density has also been linked to the
capacity of FA and its esters to regulate Nrf-2 activity, and may be a
mechanism contributing to the observed reduction of gadolinium
enhancing lesions in MS patients treated with dimethylfumarate59.
Indeed, the beneficial effects of dimethylfumarate for axon preservation and astrocyte activation in the MOG-EAE model are lost in
mice deficient in Nrf-2 gene expression60.
In conclusion, the data present here demonstrate the efficacy of
multifunctional triterpenoids in suppressing clinical and pathologic
features of disease in preclinical models of MS. These small molecules
have a unique capacity to simultaneously target intermediates that
drive production of disease-inducing cytokines, such as IL-17, while
inducing neuroprotective pathways activated through Nrf-2. Thus,
synthetic triterpenoids may serve as both therapeutic and chemopreventive agents in the context of neurodegenerative and inflammatory
diseases affecting the CNS.

Methods
Animals. C57BL/6 and SJL female mice (for EAE studies) and male Wistar rats (for
LPC studies) were housed in a pathogen free animal facility in standard cages with
free access to food and water in climate and light controlled rooms. All experimental
procedures were approved by the Animal Care and Use Committee of the Case
Western Reserve University.
EAE induction. EAE was induced in 10–12 weeks old, age matched female mice by
subcutaneous immunization on both flanks with 200 ml of emulsion containing either
Complete Fruend’s adjuvant (100 ml of incomplete Fruend’s adjuvant with 8 mg/ml
of Mycobacterium Tuberculosis and 100 ml of PBS) (DIFCO Laboratories) or
Complete Fruend’s adjuvant with 200 mg of MOG (35–55). At the time of injection
and 48 hours later 200 ng of pertussis toxin (List Biological Laboratories) was
injected intrapertonially in 100 ml of PBS. Mice were monitored for daily clinical signs
of EAE and the following criteria were used to grade clinical scores: 0-no signs of
disease;
1-limp tail; 2-moderate hind-limb weakness; 3-severe hind-limb weakness;
4-Complete hind limb paralysis; 5- quadriplegia or premoribund state; 6-death.
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Drug treatment. CDDO-Me, CDDO-EA or CDDO-TFEA were dissolved in a
minimal amount of DMSO to obtain 10 mM stock and further dissolved in 7.5%
PBST (7.5 ml Tween-80 dissolved in 100 ml of PBS) to obtain a final concentration of
100 nM. Animals were injected with 100 ml of this solution by intra-peritoneal (i.p.)
injection at the interval of 48 hours for a total of 5 injections. Therapy was initiated in
mice with varying severity of disease as noted by different clinical scores, starting after
15 days of MOG-35-55 immunization. Control animals were injected with a similar
volume of vehicle i.e. 7.5% PBST.
Histology and immunohistochemistry. On day 18 to 23 (at clinical scores 4 to 5
in control mice with EAE) and at clinical score 0 in recipients of CDDO-TFEA
treatment, mice were anesthetized and perfused with phosphate buffer saline (PBS)
followed with 4% paraformaldehyde in PBS (PFA-PBS). Brain and spinal cord were
collected and fixed in 4% PFA-PBS and embedded in paraffin to obtain 5 mm thick
sections. At least 10 to 12 serial sections were obtained from 4 different regions of the
brain (rostral cerebrum, mid cerebrum, mid brain and cerebellum with brain stem).
Spinal cord was divided into 3 parts (cervical, thoracic and lumbar). At least 5 sections
from each part and longitudinal serial sections of all regions were obtained for
representation of the entire spinal cord. Tissue sections were stained with hematoxilin
& eosin (H&E) to assess routine histology and inflammation and also with Luxol Fast
Blue and the Periodic Acid Schiff reagent to analyze myelin content. Each section was
assigned a histological score for inflammation and demylenation from 0 to 3 by an
observer blinded to sample identity, where 0 represents no lesions,
1- moderate and 3 represents severe lesions. Spinal cord sections were
immunostained with anti myloperoxidase antibody to detect granulocytes infiltration
and anti-F4/80 antibody for macrophage and microglia.
Western blot analysis. Animals were sacrificed for tissue collection at different time
points after immunization and drug treatment. Brain (further divided into forebrain,
midbrain and hindbrain) and spinal cord (further divided into cervical, thoracic and
lumbar) were collected and snap frozen. Tissue homogenates were prepared in lysis
buffer, consisting of T-PER, tissue protein extraction reagent (Pierce, Rockford, IL), a
protease inhibitor cocktail tablet (Roche, Mannheim, Germany) and 15100 diluted
phosphatase inhibitor mixtures I and II (Sigma, St. Louis, MO). Proteins were
denatured and equal amounts of proteins were electrophoresed in 4–12% bis-Tris/
polyacrylamide gels (NuPAGE; Invitrogen, Carlsbad, CA) and transferred to
nitrocellulose membranes with 0.2 mm pores (Invitrogen). The membranes were
blocked for 2 h in blocking solution (TBS containing 10% nonfat dry milk and 0.05%
Tween 20) and incubated overnight at 4uC with primary antibody diluted in blocking
solution. Incubation with horseradish peroxidase-conjugated secondary antibody
was performed at room temperature for 1 h, and immunoreactivity was detected by
using enhanced chemiluminescence (Pierce, Rockford, IL).
Oligodendrocyte primary culture. Dissociated brain cultures were made from
Sprague-Dawley rat pups at postnatal day 3, plated on poly-L-lysine/Laminin coated
coverslips and grown in 1% fetal bovine serum in DMEM supplemented with
GlutaMAXTM, Penicillin-Streptomycin, Hong’s N2 and PDGF-AA. Treatment with
vehicle (control) or vehicle 1 10 nM CDDO-TFEA began one day after dissociation
and lasted for three, six or ten days in vitro. Immunocytochemical markers of the
oligodendrocyte lineages were assayed, including A2B5 (for immature
oligodendrocyte precursor cells), and O4, (for mature marker of oligodendrocyte
precursor cells). A total of 100 to 300 total cells were counted from five different areas
in each culture and positive immunoreactive cells for A2B5 or O4 were plotted as
percentage of total cells.
Antibodies. The rabbit polyclonal anti-iNOS and anti-Hmox-1 (Santa Cruz
Biotechnology,Santa Cruz, CA) were used for Western blot analysis
(15200). For immunohistochemistry 2mg/ml of rabbit polyclonal
anti-myeloperoxidase (lot 373A603A (1); Lab Vision; Fremont, CA), or 10 mg/ml
of the rat IgG2b MAb F4/80 (clone C1:A3-1; Serotec; Raleigh, NC) were used.
Secondary horseradishperoxidase-conjugated antibodies were obtained from
AmershamBiosciences (Piscataway, NJ) and used at 152000 dilution for
immunoblots analysis and 2.5 mg/ml biotinylated rabbit anti-rat IgG secondary
antibody (Vector Laboratories; Burlingame, CA) to detect F4/80 and 2.5 mg/ml
biotinylated goat anti-rabbit IgG secondary antibody (Vector) to detect
myeloperoxidase.
ELISA. Serum levels of IL-2, Il-4, IL-6, GM-CSF, TNF and IFN-c were detected with
OptiEIA Elisa sets (BD Biosciences and IL-17 was detected with DuoSet ELISA
development System (R&D systems) as per manufacturer’s suggested protocol.
Ex vivo restimulation of T cells. Mice immunized with or without MOG(35-55)
(clinical score-5) or CDDO-TFEA treated (clinical score-0) were sacrificed and a
single cell suspension was prepared from draining lymph nodes (Inguinal and
brachial) and restimulated with 33 mg/ml of MOG (35–55) in presence or absence of
CDDO-TFEA and 50 ng/ml mIL7. Cells were seeded in a 96 well plate at a density of
23105. After 72 hours culture supernatants were collected for analysis of cytokine
secretion and cells were used for RNA preparation. For proliferation assays, 0.5 mci of
(3H) thymidine was added in cultures during last 12 hours and thymidine
incorporation was measured as cell proliferation.
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Table 1 | Quantitative PCR probes
Genes of interest
IL-17a
NOS-2
IFN-c
Hmox-1
Nrf-2
Ptgds
Grin3b
Stat2
Cd68
Csf3r
Tgfbr1
Hsd11b1
Cd74
Cd84
b-Actin

Assay ID*
Mm00439619_m1
Mm01309902_m1
Mm99999071_m1
Mm00516007_m1
Mm03053465_s1
Mm01330614_g1
Mm00504568_m1
Mm00490880_m1
Mm00839636_g1
Mm00432735_m1
Mm00436971_m1
Mm00476182_m1
Mm00658576_m1
Mm00488934_m1
Mm00607939_s1

LPC induced demyelination. Three to four months old male Wistar rats were used
for this study. Demyelination in the spinal cord was induced by LPC injection as
described previously30 with subtle modification in protocol. In brief, animals were
anesthetized with 5 ml per kg of body weight of 0.2 ml ketamine (Fort Dodge), 0.1 ml
xylazine (Lloyd Laboratories) and 0.7 ml of distilled water. After shaving and
cleaning with ethanol and betadine, a T10 laminectomy was performed in a
stereotactic apparatus (Stoelting). Using a 30-mm glass micropipette attached to a
Nano-injector (World Precision Instruments), 1.5 ml of 1% freshly prepared LPC
(Sigma) solution was infused at 15 ml/hour. The needle was kept in place for 5 min to
prevent reflux; the skin was closed and treated with Betagen (Med-Pharmex). In order
to rule out any mechanical injury control rats were subjected to similar surgical
process but in spite of LPC similar volume of PBS was injected. Rats received either
10 nM CDDO-TFEA or vechicle control at the time of LPC injection and again after
48 hours at the site of LPC injection. After 7 days all animals were sacrificed and
targeted spinal cord tissue was collected and processed for electron microscopy (for
analyzing the myelin content) and frozen tissue sections were used for immunostaing
to analyze myelin content and recruitment of oligodendrocyte and glial cells at the site
of injury.
Electron microscopy. We anesthetized and perfused the animals with Sorenson’s
buffer followed by solution containing 4% paraformaldehyde (wt/vol) and 2.5%
glutararaldehyde (vol/vol). Spinal cords were sliced into 1–2-mm sections and postfixed in the same solution overnight at 4uC, after which sections were embedded in
Araldite resin. Semi-thin sections were stained with 1% Toluidine blue staining
(wt/vol) at 65uC for a few seconds, washed several times with water and then
dehydrated and mounted with Permount. Thin sections were cut, stained with uranyl
acetate and lead citrate and analyzed. G ratios (defined as the diameter of the axon
divided by the diameter of the axon and myelin) were calculated from the outer
perimeter of the axon divided by the total perimeter of the axon and myelin. Six
pictures were randomly chosen for each mouse and 100–200 fibers per picture were
calculated. At least 6 mice per strain per time point were analyzed. The data are shown
as G ratio and total number of myelinated fibers.
Oligonucleotide microarray analysis. Total RNA was isolated using Trizol reagent
(Invitrogen) and RNeasy (Qiagen) from control and EAE mice lumbar spinal cord,
treated with or without CDDO-TFEA. Each tissue sample was derived from a
different individual mouse giving three true biological replicate samples. The yield
was quantified using NanoDrop ND-1000 Spectrophotometer (Nanodrop
Technologies, Delaware) and quality checked by conventional denaturing 1% agarose
gel analysis. For microarray analysis, extracted total RNA was biotinylated and
amplified using the IluminaH TotalPrep RNA Amplification Kit. Labeled cRNA was
then hybridized with IluminaSentrixH array (Sentrix Mouse Ref 8v1.1) according to
their standard protocol (Illumina). Following hybridization and washing, arrays were
scanned using IluminaBeadStudio (version 3.1). The raw data from all the arrays were
then exported out and analyzed using GeneSpring 7.3.1 (Agilent Technologies).
Expression of all genes on a chip was normalized globally to the expression value of
the median of the chip and each gene normalized across conditions to a median of 1.0.
This approach reduced the expression ratio for every gene in each of the control
samples to 1 and set the expression ratio for each gene in each test sample to a value
indicative of its expression relative to that in the corresponding control. The
normalized data were then filtered by volcano plot to identify genes whose expression
(in all three biological replicates) appears to be up- or down- regulated by an arbitrary
cutoff of at least 1.5 fold with p-value 5 0.05. Statistical analysis was performed on the
log expression ratios utilizing one way Students t-test analysis of variance without any
multiple testing correction. No post-hoc analysis was applied.
Quantitative Real-time polymerase chain reaction. 10 ml of total RNA
(2 micrograms) from each sample were reverse transcribed using High-Capacity
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Common Name
interleukin 17A
Nitric oxide synthase 2
hemeoxygenase 1
interferon gamma
nuclear receptor subfamily 2, group F, member 2
PGD2; PGDS
NR3B
AW496480
gp110; Scard1
Cd114; Csfgr; G-CSFR
ALK5; Alk-5; TbetaRI
Hsd11b1
Ii; CLIP; DHLAG
CDw84; SLAMF5

cDNA Reverse Transcription Kits (Applied Biosystems) that contains 10X RT Buffer;
25X dNTP Mix (100 mM); 10RT Random Primers; MultiscribeTM; Reverse
Transcriptase and nuclease-free water in a final volume of 20 ml reaction mixture.
Reverse transcription was performed using the following program on a thermal cycler
(Applied Biosystems) using only 1 cycle: (step 1) at 25uC for 10 min; (step 2) at 37uC
for 120 min; (step 3) at 85uC for 5 sec; and (step 4) at 4uC for infinity. QRT-PCR was
performed with an ABI 7500 system (Applied Biosystems) to validate the microarray
results on a number of genes apparently exhibiting differential expression. Presynthesized primers specific for the genes purchased from ABI are shown in Table 1.
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